Contrasting Chromadex Corp (CDXC) and Codexis (CDXS)
Chromadex Corp (OTCMKTS: CDXC) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.
This is a breakdown of recent ratings and recommmendations for Chromadex Corp and Codexis, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Chromadex Corp currently has a consensus target price of $5.50, suggesting a potential upside of 37.50%. Codexis has a consensus target price of $6.94, suggesting a potential upside of 18.59%. Given Chromadex Corp’s stronger consensus rating and higher probable upside, analysts plainly believe Chromadex Corp is more favorable than Codexis.
Valuation and Earnings
This table compares Chromadex Corp and Codexis’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Chromadex Corp||$20.41 million||9.03||-$6.27 million||N/A||N/A|
|Codexis||$43.16 million||6.55||-$15.16 million||($0.41)||-14.27|
Chromadex Corp has higher revenue, but lower earnings than Codexis.
Insider and Institutional Ownership
63.6% of Codexis shares are held by institutional investors. 9.8% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Chromadex Corp and Codexis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Chromadex Corp beats Codexis on 6 of the 11 factors compared between the two stocks.
Chromadex Corp Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
Codexis Company Profile
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
Receive News & Ratings for Chromadex Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex Corp and related companies with MarketBeat.com's FREE daily email newsletter.